[go: up one dir, main page]

DK0752245T3 - Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler - Google Patents

Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler

Info

Publication number
DK0752245T3
DK0752245T3 DK95110445T DK95110445T DK0752245T3 DK 0752245 T3 DK0752245 T3 DK 0752245T3 DK 95110445 T DK95110445 T DK 95110445T DK 95110445 T DK95110445 T DK 95110445T DK 0752245 T3 DK0752245 T3 DK 0752245T3
Authority
DK
Denmark
Prior art keywords
biocompatible
absorption
delivery
biodegradable nanoparticles
proteinaceous drugs
Prior art date
Application number
DK95110445T
Other languages
Danish (da)
English (en)
Inventor
Christian Grandfils
Robert Jerome
Nicole Nihant
Philippe Teyssie
Original Assignee
Europ Economic Community
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europ Economic Community filed Critical Europ Economic Community
Application granted granted Critical
Publication of DK0752245T3 publication Critical patent/DK0752245T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95110445T 1995-07-05 1995-07-05 Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler DK0752245T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95110445A EP0752245B1 (fr) 1995-07-05 1995-07-05 Nanoparticules biocompatibles et biodégradables conçues pour l'absorption et l'administration de médicaments protéiniques

Publications (1)

Publication Number Publication Date
DK0752245T3 true DK0752245T3 (da) 2002-09-09

Family

ID=8219415

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95110445T DK0752245T3 (da) 1995-07-05 1995-07-05 Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler

Country Status (10)

Country Link
US (1) US5962566A (fr)
EP (1) EP0752245B1 (fr)
JP (1) JP3486417B2 (fr)
AT (1) ATE217792T1 (fr)
CA (1) CA2226166C (fr)
DE (1) DE69526787T2 (fr)
DK (1) DK0752245T3 (fr)
ES (1) ES2177592T3 (fr)
PT (1) PT752245E (fr)
WO (1) WO1997002022A1 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2384094T3 (es) 1997-11-14 2012-06-29 Pacira Pharmaceuticals, Inc. Producción de liposomas multivesiculares
US7651875B2 (en) * 1998-06-08 2010-01-26 Borealis Technical Limited Catalysts
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
JP4751556B2 (ja) 2000-02-28 2011-08-17 ジーンシーグス， インコーポレイテッド ナノカプセルカプセル化システムおよび方法
HK1054355A1 (zh) 2000-10-02 2003-11-28 Kimberly-Clark Worldwide, Inc. 基於纳米粒子的油墨及其制造方法
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
WO2003026611A2 (fr) 2001-09-26 2003-04-03 Baxter International Inc. Preparation de nanoparticules submicroniques par dispersion et elimination d'un solvant ou d'une phase liquide
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
ATE381963T1 (de) * 2001-10-26 2008-01-15 Octoplus Technologies B V Verfahren zur herstellung von gereinigten partikeln
CA2465779A1 (fr) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions destinees a la liberation de produits a action continue
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
WO2003095515A2 (fr) * 2002-05-07 2003-11-20 The Research Foundation Of State University Of New York Procede pour preparer et cribler rapidement des formulations et compositions les contenant
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
CN101229098B (zh) * 2002-09-11 2012-02-29 田边三菱制药株式会社 微球的制备方法及相关的装置
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
US6780896B2 (en) * 2002-12-20 2004-08-24 Kimberly-Clark Worldwide, Inc. Stabilized photoinitiators and applications thereof
US7582308B2 (en) 2002-12-23 2009-09-01 Kimberly-Clark Worldwide, Inc. Odor control composition
ES2226567B1 (es) * 2003-06-20 2006-07-01 Universidad De Santiago De Compostela Nanoparticulas de acido hialuronico.
ES2232287B1 (es) * 2003-07-04 2006-11-01 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de derivados polioxietilenados.
WO2005035606A1 (fr) * 2003-10-10 2005-04-21 Samyang Corporation Copolymere sequence amphiphile et composition polymere comprenant celui-ci pour l'administration de medicaments
US7141518B2 (en) 2003-10-16 2006-11-28 Kimberly-Clark Worldwide, Inc. Durable charged particle coatings and materials
US7438875B2 (en) 2003-10-16 2008-10-21 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified silica particles
US7754197B2 (en) 2003-10-16 2010-07-13 Kimberly-Clark Worldwide, Inc. Method for reducing odor using coordinated polydentate compounds
US7582485B2 (en) 2003-10-16 2009-09-01 Kimberly-Clark Worldride, Inc. Method and device for detecting ammonia odors and helicobacter pylori urease infection
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7837663B2 (en) 2003-10-16 2010-11-23 Kimberly-Clark Worldwide, Inc. Odor controlling article including a visual indicating device for monitoring odor absorption
US7488520B2 (en) 2003-10-16 2009-02-10 Kimberly-Clark Worldwide, Inc. High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
US7413550B2 (en) 2003-10-16 2008-08-19 Kimberly-Clark Worldwide, Inc. Visual indicating device for bad breath
US7879350B2 (en) 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7794737B2 (en) 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
ES2246695B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
US7332159B2 (en) * 2004-09-30 2008-02-19 Board Of Regents Of The University Of Nebraska Method and composition for inhibiting reperfusion injury in the brain
AU2005334514B2 (en) * 2004-10-29 2009-11-26 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
CA2526541C (fr) 2004-12-01 2013-09-03 Tyco Healthcare Group Lp Nouvelles compositions de biomateriau pour dispositifs d'administration de medicaments et de modification de surface
US8263105B2 (en) 2004-12-01 2012-09-11 Tyco Healthcare Group Lp Biomaterial drug delivery and surface modification compositions
JP5050144B2 (ja) 2005-04-20 2012-10-17 満 明石 アジュバントとしてのポリアミノ酸
KR100718329B1 (ko) * 2005-09-08 2007-05-14 광주과학기술원 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법
US20070248675A1 (en) * 2005-09-08 2007-10-25 Gwangju Institute Of Science And Technology Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof
US7977103B2 (en) 2006-04-20 2011-07-12 Kimberly-Clark Worldwide, Inc. Method for detecting the onset of ovulation
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20080102127A1 (en) * 2006-10-26 2008-05-01 Gao Hai Y Hybrid lipid-polymer nanoparticulate delivery composition
DE602007008125D1 (de) * 2006-10-31 2010-09-09 Surmodics Pharmaceuticals Inc Kugelförmige polymer-teilchen
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008109347A2 (fr) * 2007-03-02 2008-09-12 Yale University Procédés d'administration ex vivo de médicaments à des greffons en utilisant des nanoparticules polymères
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
KR101005562B1 (ko) * 2008-05-01 2011-01-05 한국생명공학연구원 난용성 약물을 함유하는 균일한 크기의 고분자 나노입자제조방법
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
WO2010114768A1 (fr) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-épothilone, particules, compositions et procédés d'utilisation apparentés
WO2010114770A1 (fr) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-agent, particules, compositions et procédés d'utilisation apparentés
BRPI1014854A2 (pt) * 2009-03-30 2016-05-03 Cerulean Pharma Inc "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
US9211377B2 (en) 2009-07-30 2015-12-15 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
JP5796275B2 (ja) * 2010-06-02 2015-10-21 セイコーエプソン株式会社 分光測定器
JP6343147B2 (ja) 2010-08-30 2018-06-13 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 狭窄病変および血栓溶解療法のための剪断による制御放出
EP2841098A4 (fr) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanoparticules pour le traitement d'allergies
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
JP2016516754A (ja) 2013-04-03 2016-06-09 アラーテイン・セラピューティクス・リミテッド・ライアビリティ・カンパニーＡｌｌｅｒｔｅｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 新規のナノ粒子組成物
LT3046584T (lt) 2013-09-16 2017-10-10 Astrazeneca Ab Terapinės polimerinės nanodalelės ir jų gamybos būdai ir panaudojimas
WO2015160794A1 (fr) * 2014-04-14 2015-10-22 Ecosynthetix Ltd. Nanoparticules d'origine biologique et matériaux composites dérivés de celles-ci
CA2959660A1 (fr) 2014-09-03 2016-03-10 Genesegues, Inc. Nanoparticules therapeutiques et compositions, procedes et systemes associes
WO2017147240A1 (fr) 2016-02-23 2017-08-31 Tarveda Therapeutics, Inc. Conjugués et particules ciblant hsp90 et leurs formulations
WO2018085658A1 (fr) * 2016-11-03 2018-05-11 Case Western Reserve University Constructions de nanoparticules virales traitées par fusion
CA3194232A1 (fr) 2020-09-29 2022-04-07 Daniel Beard Traitement d'un accident vasculaire cerebral
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
WO2023064464A1 (fr) 2021-10-14 2023-04-20 Pacira Pharmaceuticals, Inc. Formulations de liposomes multivésiculaires de bupivacaïne et leurs utilisations
US12156940B1 (en) 2024-05-20 2024-12-03 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12280149B1 (en) 2024-05-20 2025-04-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US4968350A (en) * 1987-04-16 1990-11-06 Christian Bindschaedler Process for preparing a powder of water-insoluble polymer which can be redispersed in a liquid phase, the resulting powder and utilization thereof
FR2660556B1 (fr) * 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FR2678168B1 (fr) * 1991-06-28 1993-09-03 Rhone Poulenc Rorer Sa Nanoparticules ayant un temps de capture par le dysteme reticulo endothelial allonge.
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
ES2034891B1 (es) * 1991-08-08 1993-12-16 Cusi Lab Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
ES2078175B1 (es) * 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.

Also Published As

Publication number Publication date
PT752245E (pt) 2002-09-30
US5962566A (en) 1999-10-05
WO1997002022A1 (fr) 1997-01-23
ES2177592T3 (es) 2002-12-16
CA2226166C (fr) 2001-05-08
ATE217792T1 (de) 2002-06-15
DE69526787T2 (de) 2002-12-05
CA2226166A1 (fr) 1997-01-23
JPH11504655A (ja) 1999-04-27
DE69526787D1 (de) 2002-06-27
JP3486417B2 (ja) 2004-01-13
EP0752245B1 (fr) 2002-05-22
EP0752245A1 (fr) 1997-01-08

Similar Documents

Publication Publication Date Title
DK0752245T3 (da) Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler
DE69121675D1 (de) Mikrosphäre enthaltende pharmazeutische Zusammensetzung mit kontrollierter Freigabe und Verfahren zur Herstellung
ATE516049T1 (de) Formulierung zur gesteuerten arzneistofffreisetzung durch kombination hydrophiler und hydrophober stoffe
IS5599A (is) Fjölliðusamsetningar á vökvaformi fyrir stýrða losun á lífvirkum efnum
ES2113906T3 (es) Composiciones polimericas utiles como implantes con administracion controlada.
ATE108650T1 (de) Methode und zusammensetzung zur oralen verabreichung von bioaktiven mitteln zur peyer's flecken.
DK1126822T3 (da) Flydende tilförselspræparater med reguleret frigivelse og lav initiel lægemiddelafgivelse
DK0430287T4 (da) Doseringsenheder til vedvarende afgivelse af et lægemiddel
ATE92312T1 (de) Pharmazeutische zubereitung mit verzoegerter freisetzung und seine herstellung.
ATE438424T1 (de) Stent fur ein blutgefass und material fur eine vaskulare endoprothese
NO912769D0 (no) Avleveringssystem for medikamenter.
ES2149250T3 (es) Dispositivo para la administracion de medicamentos con liberacion controlada.
WO1996040073A3 (fr) Composition permettant la liberation prolongee d'erythropoietine sans agregation
AU4800999A (en) Preparation capable of releasing drug at target site in intestine
DK0826376T3 (da) Sammensætning til oral indgivelse
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
DE60225481D1 (de) Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung
ATE327737T1 (de) Verfahren zur herstellung von arzneistoffgranulatkörnern, die arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische zubereitungen
ATE87201T1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
AU6889196A (en) Long active composition for rectal administration
DE60035421D1 (de) Chitosanpulver enthaltende feste zubereitungen und verfahren zu deren herstellung
ATE265234T1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
DE68907091D1 (de) Scleroglucan und wirkstoff enthaltende pharmazeutische tabletten und kapselgranulate.